A novel reduced-intensity conditioning regimen for unrelated umbilical cord blood transplantation in children with nonmalignant diseases

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 3, 2014, Pages 326-336

  Parikh, Suhag H ^a   Mendizabal, Adam ^b   Benjamin, Cara L ^c   Komanduri, Krishna V ^c   Antony, Jeyaraj ^d   Petrovic, Aleksandra ^e   Hale, Gregory ^e   Driscoll, Timothy A ^a   Martin, Paul L ^a   Page, Kristin M ^a   Flickinger, Ketti ^a   Moffet, Jerelyn ^a   Niedzwiecki, Donna ^a   Kurtzberg, Joanne ^a   Szabolcs, Paul ^d  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b EMMES CORPORATION   (United States)

^c UNIVERSITY OF MIAMI   (United States)

^d CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^e JOHNS HOPKINS ALL CHILDREN S HOSPITAL   (United States)

Author keywords

Hemophagocytic lymphohistiocytosis (HLH); Nonmalignant diseases; Pediatric disorders; Reduced intensity conditioning; Thalassemia; Umbilical cord blood transplantation

Indexed keywords

ALEMTUZUMAB; FLUDARABINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYUREA; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; MELPHALAN; MYCOPHENOLIC ACID; T LYMPHOCYTE RECEPTOR; TACROLIMUS; THIOTEPA;

ACUTE GRAFT VERSUS HOST DISEASE; ADENOVIRUS INFECTION; ARTICLE; BLACKFAN DIAMOND ANEMIA; BLOOD TRANSFUSION REACTION; BRONCHIECTASIS; CAUSE OF DEATH; CHILD; CHILDHOOD DISEASE; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LUNG DISEASE; CLINICAL ARTICLE; COMORBIDITY; CORD BLOOD STEM CELL TRANSPLANTATION; CRYOPRESERVATION; CYTOKINE RELEASE; CYTOKINE RESPONSE; CYTOMEGALOVIRUS INFECTION; DENDRITIC CELL; ENGRAFTMENT; EPSTEIN BARR VIRUS INFECTION; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMOGLOBINOPATHY; HEMORRHAGIC CYSTITIS; HLA TYPING; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERBARIC OXYGEN; IMMUNE DEFICIENCY; IMMUNOPHENOTYPING; INFANT; LYMPHOCYTE; MALE; METABOLIC DISORDER; MUCOSA INFLAMMATION; NEUROLOGIC DISEASE; NEUTROPHIL; NONMALIGNANT DISEASE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERICARDIAL EFFUSION; PHASE 1 CLINICAL TRIAL; PILOT STUDY; PNEUMONIA; PRESCHOOL CHILD; PROSPECTIVE STUDY; REDUCED INTENSITY CONDITIONING; SCHOOL CHILD; SLEEP DISORDERED BREATHING; T LYMPHOCYTE; THROMBOCYTE; VIREMIA; VIRUS INFECTION; VIRUS MENINGITIS;

HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH); NONMALIGNANT DISEASES; PEDIATRIC DISORDERS; REDUCED-INTENSITY CONDITIONING; THALASSEMIA; UMBILICAL CORD BLOOD TRANSPLANTATION;

ANEMIA, DIAMOND-BLACKFAN; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; COMMON VARIABLE IMMUNODEFICIENCY; CORD BLOOD STEM CELL TRANSPLANTATION; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMOGLOBINOPATHIES; HLA ANTIGENS; HUMANS; INFANT; MALE; METABOLIC DISEASES; SURVIVAL ANALYSIS; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; UNRELATED DONORS;

EID: 84896709665     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.11.021     Document Type: Article

References (65)

1. Tolar J., Mehta P.A., Walters M.C. Hematopoietic cell transplantation for nonmalignant disorders. Biol Blood Marrow Transplant 2012, 18:S166-S171.
2. Szabolcs P., Cavazzana-Calvo M., Fischer A., Veys P. Bone marrow transplantation for primary immunodeficiency diseases. Pediatr Clin North Am 2010, 57:207-237.
3. Boelens J.J., Prasad V.K., Tolar J., et al. Current international perspectives on hematopoietic stem cell transplantation for inherited metabolic disorders. Pediatr Clin North Am 2010, 57:123-145.
4. Kurtzberg J., Laughlin M., Graham M.L., et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. NEngl J Med 1996, 335:157-166.
5. Eapen M., Rubinstein P., Zhang M.J., et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet 2007, 369:1947-1954.
6. Prasad V.K., Kurtzberg J. Umbilical cord blood transplantation for non-malignant diseases. Bone Marrow Transplant 2009, 44:643-651.
7. Gluckman E. Milestones in umbilical cord blood transplantation. Blood Reviews 2011, 25:255-259.
8. Kurtzberg J., Prasad V.K., Carter S.L., et al. Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. Blood 2008, 112:4318-4327.
9. Sanders J.E. Growth and development after hematopoietic cell transplant in children. Bone Marrow Transplant 2007, 41:223-227.
10. Eapen M., Ahn K.W., Orchard P.J., et al. Long-term survival and late deaths after hematopoietic cell transplantation for primary immunodeficiency diseases and inborn errors of metabolism. Biol Blood Marrow Transplant 2012, 18:1438-1445.
11. Andreani M., Nesci S., Lucarelli G., et al. Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation. Bone Marrow Transplant 2000, 25:401-404.
12. Walters M.C., Patience M., Leisenring W., et al. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant 2001, 7:665-673.
13. Veys P. Reduced intensity transplantation for primary immunodeficiency disorders. Immunol Allergy Clinics North Am 2010, 30:103-124.
14. Marsh R.A., Vaughn G., Kim M.-O., et al. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood 2010, 116:5824-5831.
15. Hsieh M.M., Kang E.M., Fitzhugh C.D., et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. New Engl J Med 2009, 361:2309-2317.
16. Jacobsohn D.A., Duerst R., Tse W., Kletzel M. Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant diseases in children. Lancet 2004, 364:156-162.
17. Krishnamurti L., Kharbanda S., Biernacki M.A., et al. Stable long-term donor engraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant 2008, 14:1270-1278.
18. Shenoy S., Grossman W.J., DiPersio J., et al. Anovel reduced-intensity stem cell transplant regimen for nonmalignant disorders. Bone Marrow Transplant 2004, 35:345-352.
19. Kamani N.R., Walters M.C., Carter S., et al. Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant 2012, 18:1265-1272.
20. Ruggeri A., Eapen M., Scaravadou A., et al. umbilical cord blood transplantation for children with thalassemia and sickle cell disease. Biol Blood Marrow Transplant 2011, 17:1375-1382.
21. Radhakrishnan K., Bhatia M., Geyer M.B., et al. Busulfan, fludarabine, and alemtuzumab conditioning and unrelated cord blood transplantation in children with sickle cell disease. Biol Blood Marrow Transplant 2013, 19:676-677.
22. Satwani P., Jin Z., Duffy D., et al. Transplantation-related mortality, graft failure, and survival after reduced-toxicity conditioning and allogeneic hematopoietic stem cell transplantation in 100 consecutive pediatric recipients. Biol Blood Marrow Transplant 2013, 19:552-561.
23. Rubinstein P., Dobrila L., Rosenfield R.E., et al. Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution. Proc Natl Acad Sci U S A 1995, 92:10119-10122.
24. Prasad V.K., Mendizabal A., Parikh S.H., et al. Unrelated donor umbilical cord blood transplantation for inherited metabolic disorders in 159 pediatric patients from a single center: influence of cellular composition of the graft on transplantation outcomes. Blood 2008, 112:2979-2989.
25. Leen A.M., Bollard C.M., Mendizabal A.M., et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 2013, 121:5113-5123.
26. Szabolcs P., Park K.-D., Reese M., et al. Absolute values of dendritic cell subsets in bone marrow, cord blood, and peripheral blood enumerated by a novel method. Stem Cells 2003, 21:296-303.
27. Szabolcs P., Park K.-D., Reese M., et al. Coexistent naïve phenotype and higher cycling rate of cord blood T cells as compared to adult peripheral blood. Exp Hematol 2003, 31:708-714.
28. Kanda J., Chiou L.-W., Szabolcs P., et al. Immune recovery in adult patients after myeloablative dual umbilical cord blood, matched sibling, and matched unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012, 18:1664-1676.e1.
29. Szabolcs P., Park K.-D., Marti L., et al. Superior depletion of alloreactive T cells from peripheral blood stem cell and umbilical cord blood grafts by the combined use of trimetrexate and interleukin-2 immunotoxin. Biol Blood Marrow Transplant 2004, 10:772-783.
30. Davis C.C., Marti L.C., Sempowski G.D., et al. Interleukin-7 permits Th1/Tc1 maturation and promotes exvivo expansion of cord blood T cells: A Critical Step toward Adoptive Immunotherapy after Cord Blood Transplantation. Cancer Res 2010, 70:5249-5258.
31. Komanduri K.V., St.John L.S., de Lima M., et al. Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood 2007, 110:4543-4551.
32. Gooley T., Leisenring W., Crowley J., Storer B. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999, 18:695-706.
33. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995, 15:825-828.
34. Shulman H., Sullivan K., Weiden P., et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980, 69:204-217.
35. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association 1958, 53:457-481.
36. Parkman R., Cohen G., Carter S.L., et al. Successful immune reconstitution decreases leukemic relapse and improves survival in recipients of unrelated cord blood transplantation. Biol Blood Marrow Transplant 2006, 12:919-927.
37. Moretta A., Maccario R., Fagioli F., et al. Analysis of immune reconstitution in children undergoing cord blood transplantation. Exp Hematol 2001, 29:371-379.
38. Rénard C., Barlogis V., Mialou V., et al. Lymphocyte subset reconstitution after unrelated cord blood or bone marrow transplantation in children. Br J Haematol 2011, 152:322-330.
39. Thomson B.G., Robertson K.A., Gowan D., et al. Analysis of engraftment, graft-versus-host disease, and immune recovery following unrelated donor cord blood transplantation. Blood 2000, 96:2703-2711.
40. Comans-Bitter W.M., de Groot R., van den Beemd R., et al. Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations. JPediatr 1997, 130:388-393.
41. Bizzetto R., Bonfim C., Rocha V., et al. Outcomes after related and unrelated umbilical cord blood transplantation for hereditary bone marrow failure syndromes other than Fanconi anemia. Haematologica 2011, 96:134-141.
42. Frangoul H., Wang L., Harrell F.E., et al. Unrelated umbilical cord blood transplantation in children with immune deficiency: results of a multicenter study. Bone Marrow Transplant 2009, 45:283-288.
43. Gennery A., Cant A.J. Cord blood stem cell transplantation in primary immune deficiencies. Curr Opin Allergy Clin Immunol 2007, 7:528-534.
44. Bhattacharya A., Slatter M.A., Chapman C.E., et al. Single centre experience of umbilical cord stem cell transplantation for primary immunodeficiency. Bone Marrow Transplant 2005, 36:295-299.
45. Fernandes J.F., Rocha V., Labopin M., et al. Transplantation in patients with SCID: mismatched related stem cells or unrelated cord blood?. Blood 2012, 119:2949-2955.
46. Adamkiewicz T., Mehta P., Boyer M., et al. Transplantation of unrelated placental blood cells in children with high-risk sickle cell disease. Bone Marrow Transplant 2004, 34:405-411.
47. Adamkiewicz T.V., Szabolcs P., Haight A., et al. Unrelated cord bloodtransplantation in children with sickle cell disease: Review of four-center experience. Pediatric Transplantation 2007, 11:641-644.
48. Chow R.Y., Jaing T.H., Chan L.L., et al. Unrelated cord blood transplantation (CBT) of 101 hemoglobinopathy (HGB) patients. Biol Blood Marrow Transplant 2012, 18:S268.
49. Lang P.J., Mueller I., Teltschik H., et al. Low transplant related toxicity and mortality after transplantation of CD3/CD19 depleted haploidentical stem cells with reduced intensity conditioning in children. Blood 2007, 110:3076.
50. Hara J., Osugi Y., Ohta H., et al. Double-conditioning regimens consisting of thiotepa, melphalan and busulfan with stem cell rescue for the treatment of pediatric solid tumors. Bone Marrow Transplant 1998, 22:7-12.
51. Ciurea S.O., Qureshi S., Rondon G., et al. Sustained engraftment using fludarabine, melphalan and thiotepa conditioning for haploidentical stem cell transplantation. Blood 2007, 110:5081.
52. Terenzi A., Lubin I., Lapidot T., et al. Enhancement of T cell-depleted bone marrow allografts in mice by thiotepa. Transplantation 1990, 50:717-720.
53. Down J.D., Westerhof G.R., Boudewijn A., et al. Thiotepa improves allogeneic bone marrow engraftment without enhancing stem cell depletion in irradiated mice. Bone Marrow Transplant 1998, 21:327-330.
54. Rosales F., Peylan-Ramu N., Cividalli G., et al. The role of thiotepa in allogeneic bone marrow transplantation for genetic diseases. Bone Marrow Transplant 1999, 23:861-865.
55. Locatelli F., Rocha V., Reed W., et al. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood 2003, 101:2137-2143.
56. Mazur M., Kurtzberg J., Halperin E.C., et al. Transplantation of a child with sickle cell anemia with an unrelated cord blood unit after reduced intensity conditioning. JPediatr Hematol Oncol 2006, 28:840-844.
57. Uchida N., Friera A.M., He D., et al. Hydroxyurea can be used to increase mouse c-kit+Thy-1.1loLin-/loSca-1+ hematopoietic cell number and frequency in cell cycle invivo. Blood 1997, 90:4354-4362.
58. Page K.M., Zhang L., Mendizabal A., et al. Total colony-forming units are a strong, independent predictor of neutrophil and platelet engraftment after unrelated umbilical cord blood transplantation: a single-center analysis of 435 cord blood transplants. Biol Blood Marrow Transplant 2011, 17:1362-1374.
59. Eapen M., Klein J.P., Ruggeri A., et al. Is allele-level HLA-matching relevant for single umbilical cord blood transplants?. Bone Marrow Transplant 2013, 48:2.
60. Bacigalupo A., Ballen K., Rizzo D., et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009, 15:1628-1633.
61. Baker K.S., Filipovich A.H., Gross T.G., et al. Unrelated donor hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis. Bone Marrow Transplant 2008, 42:175-180.
62. Cooper N., Rao K., Gilmour K., et al. Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis. Blood 2006, 107:1233-1236.
63. Sawada A., Ohga S., Ishii E., et al. Feasibility of reduced-intensity conditioning followed by unrelated cord blood transplantation for primary hemophagocytic lymphohistiocytosis: a nationwide retrospective analysis in Japan. Int J Hematol 2013, 98:223-230.
64. Hwang E.I., Camitta M.G.W., Vinesett R., et al. Pericardial effusion following unrelated umbilical cord blood transplantation: analysis in a cohort of 423 pediatric patients transplanted at a single center. Biol Blood Marrow Transplant 2009, 15:73.
65. Lee F., Madrigal A., Shaw B., Saudemont A. Study of the effects of Campath on cord blood and peripheral blood cells. Bone Marrow Transplant 2013, 48:241.